Literature DB >> 9405430

Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells.

A T Ferguson1, P M Vertino, J R Spitzner, S B Baylin, M T Muller, N E Davidson.   

Abstract

The cytosine analog 5-aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase. Its cytotoxicity has been attributed to several possible mechanisms including reexpression of growth suppressor genes and formation of covalent adducts between DNA methyltransferase and 5-aza-2'-deoxycytidine-substituted DNA which may lead to steric inhibition of DNA function. In this study, we use a panel of human breast cancer cell lines as a model system to examine the relative contribution of two mechanisms, gene reactivation and adduct formation. Estrogen receptor-negative cells, which have a hypermethylated estrogen receptor gene promoter, are more sensitive than estrogen receptor-positive cells and underwent apoptosis in response to 5-aza-2'-deoxycytidine. For the first time, we show that reactivation of a gene silenced by methylation, estrogen receptor, plays a major role in this toxicity in one estrogen receptor-negative cell line as treatment of the cells with anti-estrogen-blocked cell death. However, drug sensitivity of other tumor cell lines correlated best with increased levels of DNA methyltransferase activity and formation DNA.DNA methyltransferase adducts as analyzed in situ. Therefore, both reexpression of genes like estrogen receptor and formation of covalent enzyme. DNA adducts can play a role in 5-aza-2'-deoxycytidine toxicity in cancer cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9405430     DOI: 10.1074/jbc.272.51.32260

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Mechanisms of 5-azacytidine (5AzC)-induced toxicity in the rat foetal brain.

Authors:  Masaki Ueno; Kei-Ichi Katayama; Hiroyuki Nakayama; Kunio Doi
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

Review 2.  Molecular and cellular determinants of estrogen receptor alpha expression.

Authors:  Joseph J Pinzone; Holly Stevenson; Jeannine S Strobl; Patricia E Berg
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  Importance of the tmRNA system for cell survival when transcription is blocked by DNA-protein cross-links.

Authors:  H Kenny Kuo; Rachel Krasich; Ashok S Bhagwat; Kenneth N Kreuzer
Journal:  Mol Microbiol       Date:  2010-09-16       Impact factor: 3.501

4.  Mutants of Aspergillus nidulans affected in asexual development.

Authors:  Josy Fraccaro Marins; Marialba Avezum Alves Castro-Prado
Journal:  J Genet       Date:  2006-04       Impact factor: 1.166

5.  Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer.

Authors:  Kai Tao; Shipeng Guo; Rui Chen; Chengcheng Yang; Lei Jian; Haochen Yu; Shengchun Liu
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 6.  The future of epigenetic therapy in solid tumours--lessons from the past.

Authors:  Nilofer Azad; Cynthia A Zahnow; Charles M Rudin; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

Review 7.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Authors:  Wen Zhou; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

8.  Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells.

Authors:  Pranapda Aumsuwan; Shabana I Khan; Ikhlas A Khan; Bharathi Avula; Larry A Walker; William G Helferich; Benita S Katzenellenbogen; Asok K Dasmahapatra
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-08-23       Impact factor: 2.416

Review 9.  Epigenetic alterations in a murine model for chronic lymphocytic leukemia.

Authors:  Shih-Shih Chen; Mara H Sherman; Erin Hertlein; Amy J Johnson; Michael A Teitell; John C Byrd; Christoph Plass
Journal:  Cell Cycle       Date:  2009-11-15       Impact factor: 4.534

10.  A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Authors:  Jianqing Lin; Jill Gilbert; Michelle A Rudek; James A Zwiebel; Steve Gore; Anchalee Jiemjit; Ming Zhao; Sharyn D Baker; Richard F Ambinder; James G Herman; Ross C Donehower; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.